Navigation Links
Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer

SAN DIEGO, May 23, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of David A. Ramsay as Chief Financial Officer.  Mr. Ramsay was most recently Vice President, Corporate Development at Halozyme.


"With his established financial management experience and his recent commercial and operational experience gained by working in our commercial group for the last four years, David brings strong assets to advance the company, manage financial growth and deliver value for our shareholders," said Gregory I. Frost , Ph.D., President and Chief Executive Officer at Halozyme.  Mr. Ramsay replaces Kurt Gustafson who is leaving the company to pursue other opportunities. "We wish Kurt the best and sincerely thank him for his years of service helping to build our business," continued Frost. 

Mr. Ramsay has had a distinguished tenure at Halozyme, joining in 2003 as Chief Financial Officer before serving as Vice President, Corporate Development. His numerous achievements and accomplishments at Halozyme include spearheading the process of taking Halozyme public in 2004, negotiating and executing equity investments made by Roche and Baxter, negotiating and signing the Baxter Hylenex collaboration, and ultimately leading the effort to reintroduce Hylenex to the market in late 2011.  Prior to Halozyme, he served in various financial roles including Vice President, Chief Financial Officer of Lathian Systems.  Prior to Lathian, Mr. Ramsay was Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company.  Mr. Ramsay joined Valeant from ARCO, where he spent four years in various financial roles, most recently serving as Manager, Financial Planning & Analysis for the company's Retail Marketing division.

About Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need.  The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma, Intrexon, and Pfizer. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Investor Contact:
David Ramsay
Halozyme Therapeutics

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Reports First Quarter 2013 Financial Results
2. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
3. Halozyme Therapeutics Names Matt Posard to Board of Directors
4. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
5. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
6. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
7. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Halozyme to Host Third Quarter Financial Results Conference Call
10. Halozyme Reports Second Quarter 2012 Financial Results
11. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Thanks to a donor with ... Mary,s Medical Center,s Sister Diane Grassilli Center for Women,s ... in San Francisco . ... stepped forward with a gift of $617,320 that allowed ... Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... planning and monitoring. Their Care Plan software creates an agreement between the ... patient care plan, including financial, scheduling, monitoring, notification, and projections. Click ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a ... Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in ... and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the ...
(Date:11/24/2015)... ... November 25, 2015 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... upcoming Clinical Trial Supply East Asia Conference, to be held at the InterContinental ...
Breaking Medicine News(10 mins):